From the company's web site (http://www.polymedix.com)
PolyMedix is developing novel, first in class therapies for serious, life threatening, acute disorders. Using our proprietary computational drug design technology, we have created our two lead product candidates which have completed Phase 1B clinical trials. PMX-60056 is a synthetic, small-molecule designed as an anticoagulant reversing agent and PMX-30063 is an antibiotic that mimics natural host defense proteins. Phase 2 studies for both of these products are planned to commence during 2010.
PolyMedix’s approach to developing high-value therapeutic drugs is with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix is a publicly traded company (OTC BB:PYMX).
I first learned of the company from a post by Biomaven
Message 26093658
Message 26431043
and later found some by Catfish
Message 25784159
Message 25814715
Message 25895872
Message 25975821 |
